» Articles » PMID: 38108546

Metabolic Pathways in Immune Senescence and Inflammaging: Novel Therapeutic Strategy for Chronic Inflammatory Lung Diseases. An EAACI Position Paper from the Task Force for Immunopharmacology

Abstract

The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune-driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence-related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for strategies aimed at disease prevention and supporting healthy aging.

Citing Articles

The antioxidant barrier, oxidative/nitrosative stress, and protein glycation in allergy: from basic research to clinical practice.

Biedrzycki G, Wolszczak-Biedrzycka B, Dorf J, Maciejczyk M Front Immunol. 2024; 15:1440313.

PMID: 39703514 PMC: 11655330. DOI: 10.3389/fimmu.2024.1440313.


The role of the cGAS-STING pathway in chronic pulmonary inflammatory diseases.

Tian M, Li F, Pei H, Liu X, Nie H Front Med (Lausanne). 2024; 11:1436091.

PMID: 39540037 PMC: 11557406. DOI: 10.3389/fmed.2024.1436091.


Malnutrition and Allergies: Tipping the Immune Balance towards Health.

Vassilopoulou E, Venter C, Roth-Walter F J Clin Med. 2024; 13(16).

PMID: 39200855 PMC: 11355500. DOI: 10.3390/jcm13164713.


The activation of cGAS-STING pathway causes abnormal uterine receptivity in aged mice.

Chen S, Shi W, Ran F, Liu C, Luo H, Wu L Aging Cell. 2024; 23(11):e14303.

PMID: 39113346 PMC: 11561655. DOI: 10.1111/acel.14303.


Addition of Polyphenols to Drugs: The Potential of Controlling "Inflammaging" and Fibrosis in Human Senescent Lung Fibroblasts In Vitro.

Godoy M, Monteiro G, Moraes B, Macedo J, Goncalves G, Gambero A Int J Mol Sci. 2024; 25(13).

PMID: 39000270 PMC: 11241747. DOI: 10.3390/ijms25137163.


References
1.
Assmus B, Urbich C, Aicher A, Hofmann W, Haendeler J, Rossig L . HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003; 92(9):1049-55. DOI: 10.1161/01.RES.0000070067.64040.7C. View

2.
Triana-Martinez F, Picallos-Rabina P, Da Silva-Alvarez S, Pietrocola F, Llanos S, Rodilla V . Identification and characterization of Cardiac Glycosides as senolytic compounds. Nat Commun. 2019; 10(1):4731. PMC: 6803708. DOI: 10.1038/s41467-019-12888-x. View

3.
Yonchuk J, Foley J, Bolognese B, Logan G, Wixted W, Kou J . Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress. J Pharmacol Exp Ther. 2017; 363(1):114-125. DOI: 10.1124/jpet.117.241794. View

4.
Simpson R, Lowder T, Spielmann G, Bigley A, Lavoy E, Kunz H . Exercise and the aging immune system. Ageing Res Rev. 2012; 11(3):404-20. DOI: 10.1016/j.arr.2012.03.003. View

5.
Xie N, Zhang L, Gao W, Huang C, Huber P, Zhou X . NAD metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020; 5(1):227. PMC: 7539288. DOI: 10.1038/s41392-020-00311-7. View